Efficacy and Safety of Plasma Exchange With Albutein® 5% in Participants With Amyotrophic Lateral Sclerosis
Pilot Study to Evaluate the Efficacy and Safety of Plasma Exchange With Albutein® 5% in Patients With Amyotrophic Lateral Sclerosis
Sponsor: Grifols Biologicals, LLC
Listed as NCT02872142, this PHASE2 trial focuses on Amyotrophic Lateral Sclerosis and remains completed. Sponsored by Grifols Biologicals, LLC, it has been updated 12 times since 2016, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jun 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jun 2021 [monthly]
Completed PHASE2
-
Apr 2020 — Jan 2021 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
▶ Show 7 earlier versions
-
Aug 2019 — Apr 2020 [monthly]
Active Not Recruiting PHASE2
-
May 2019 — Aug 2019 [monthly]
Active Not Recruiting PHASE2
-
Mar 2019 — May 2019 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Mar 2019 [monthly]
Recruiting PHASE2
-
Apr 2018 — Jun 2018 [monthly]
Recruiting PHASE2
-
Feb 2017 — Apr 2018 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Aug 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Grifols Biologicals, LLC
- Grifols Therapeutics LLC
For direct contact, visit the study record on ClinicalTrials.gov .